RecruitingNot Applicable

Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence

France3,400 participantsStarted 2020-05-28

Plain-language summary

The main objective of the BREIZH-Cohorte study is to determine the incidence of recurrent short, medium and long-term thromboembolic venous disease as well as risk factors for recurrence in two specific populations: patients under 50 years of age, men and women (5 year recurrence), as well as cancer patients (all ages) (1 year recurrence).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject aged 18 or over, or a minor with the consent of the parents and the minor, presenting with a thromboembolic venous disease * 50 and under or any age if active cancer * Affiliated to social security * Accepting to participate in the study. Exclusion Criteria: * Inability to communicate (comprehension disorder). * Refusal to participate.

What they're measuring

Recurrence of thromboembolic venous disease

Timeframe: 20 years

Trial details

NCT IDNCT04297085

SponsorUniversity Hospital, Brest

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2050-04

Contact for this trial

Francis COUTURAUD, MD, PHD

02 98 34 73 47 francis.couturaud@chu-brest.fr

View on ClinicalTrials.gov More Thromboembolic Venous Disease trials